Table 1.
Principal clinical studies with hypomethylating agents in IPSS higher-risk MDS patients
N indicates number of patients; ORR, overall response rate; OS, overall survival; RD, response duration; TID, 3 times/d; SC, subcutaneous; NR, not reported; and CR, complete response.
